Notice for leniolisib (Pharming Australia Pty Ltd)
Active ingredients
leniolisib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 to 11 years
Therapeutic area
Immunology